ARSB and mucopolysaccharidosis type 6: Recombinant human ARSB is used successfully in enzyme replacement therapy of congenital ARSB deficiency, Mucopolysaccharidosis VI, by the administration of a weekly dose of 1.0 mg/kg IV [42].